Iovance Biotherapeutics (IOVA) Cost of Revenue (2023 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Cost of Revenue of $42.5 million for Q1 2026, down 0.51% year-over-year from $42.7 million in Q1 2025, and down 1.42% quarter-over-quarter from $43.1 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Cost of Revenue (2023 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Cost of Revenue for 4 consecutive years, with $42.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cost of Revenue fell 0.51% year-over-year to $42.5 million; the TTM figure through Mar 2026 stood at $180.8 million (up 26.05% YoY), while the FY2025 annual figure was $173.2 million, up 85.72% from the prior year.
- Cost of Revenue retreated to $42.5 million in Q1 2026 per IOVA's latest filing, from $43.1 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $56.7 million in Q2 2025 and bottomed at -$5.4 million in Q4 2023.
- Historically, Cost of Revenue has averaged $27.7 million across 4 years, with a median of $34.7 million in 2024.
- Annual changes were most pronounced in 2024 — Cost of Revenue soared 1430.15% — and 2026, when it slipped 0.51%.
- Iovance Biotherapeutics' Cost of Revenue stood at -$5.4 million in 2023, then jumped by 805.41% to $37.8 million in 2024, then advanced by 14.08% to $43.1 million in 2025, then fell by 1.42% to $42.5 million in 2026.
- Business Quant data shows IOVA's Cost of Revenue at $42.5 million in Q1 2026, $43.1 million in Q4 2025, and $38.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 43.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.60 Mn |
| Jun 30, 2026 | 43.60 Mn |
| Mar 31, 2026 | 42.50 Mn |
| Mar 31, 2026 | 42.50 Mn |
| Dec 31, 2025 | 43.11 Mn |
| Dec 31, 2025 | 43.11 Mn |
| Sep 30, 2025 | 38.48 Mn |
| Sep 30, 2025 | 38.48 Mn |
| Jun 30, 2025 | 56.66 Mn |
| Jun 30, 2025 | 56.66 Mn |
| Mar 31, 2025 | 42.72 Mn |
| Mar 31, 2025 | 42.72 Mn |
| Dec 31, 2024 | 37.79 Mn |
| Dec 31, 2024 | 37.79 Mn |
| Sep 30, 2024 | 31.52 Mn |
| Sep 30, 2024 | 31.52 Mn |
| Jun 30, 2024 | 31.37 Mn |
| Jun 30, 2024 | 31.37 Mn |
| Mar 31, 2024 | 7.26 Mn |
| Mar 31, 2024 | 7.26 Mn |